Research

Hormonal

Use of GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide, dulaglutide) for weight loss is associated with an emerging adverse effect of alopecia, primarily presenting as telogen effluvium or androgenetic alopecia.

If you are using a GLP-1 medication for weight loss and notice increased hair shedding, do not immediately stop the medication. This is a reported side effect, often presenting as temporary shedding (telogen effluvium) linked to metabolic stress or rapid weight loss. Consult a dermatologist to confirm the type of hair loss; it may be manageable without discontinuing your weight loss treatment.

ModerateSupportsLOW confidence
Alopecia has recently been reported as a potential emerging adverse effect associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs), which are widely prescribed for weight loss... an increasing number of reports describe hair loss events in patients treated with semaglutide, liraglutide, tirzepatide, and dulaglutide.
Rosa López-Gigosos et al. · Cureus · 2025

Why this rating

Evidence is based on pharmacovigilance reports and retrospective cohorts with high risk of bias; no randomized controlled trials confirmed the causal link.

Source

Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review

Rosa López-Gigosos et al. · Cureus · 2025

DOI 10.7759/cureus.90021

narrative_review
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →